Login / Signup

Liver Fibrosis Stages Affect Organic Cation Transporter 1/2 Activities in Hepatitis C Virus-Infected Patients.

Matheus De Lucca ThomazCarolina Pinto VieiraJuciene Aparecida CarisMaria Paula MarquesAdriana RochaTiago Antunes PazRosamar Eulira Fontes RezendeVera Lucia Lanchote
Published in: Pharmaceuticals (Basel, Switzerland) (2024)
This study aims to evaluate the impact of liver fibrosis stages of chronic infection with hepatitis C virus (HCV) on the in vivo activity of organic cation transporters (hepatic OCT1 and renal OCT2) using metformin (MET) as a probe drug. Participants allocated in Group 1 ( n = 15, mild to moderate liver fibrosis) or 2 ( n = 13, advanced liver fibrosis and cirrhosis) received a single MET 50 mg oral dose before direct-acting antiviral (DAA) drug treatment (Phase 1) and 30 days after achieving sustained virologic response (Phase 2). OCT1/2 activity (MET AUC 0-24 ) was found to be reduced by 25% when comparing the two groups in Phase 2 (ratio 0.75 (0.61-0.93), p < 0.05) but not in Phase 1 (ratio 0.81 (0.66-0.98), p > 0.05). When Phases 1 and 2 were compared, no changes were detected in both Groups 1 (ratio 1.10 (0.97-1.24), p > 0.05) and 2 (ratio 1.03 (0.94-1.12), p > 0.05). So, this study shows a reduction of approximately 25% in the in vivo activity of OCT1/2 in participants with advanced liver fibrosis and cirrhosis after achieving sustained virologic response and highlights that OCT1/2 in vivo activity depends on the liver fibrosis stage of chronic HCV infection.
Keyphrases
  • liver fibrosis
  • hepatitis c virus
  • optical coherence tomography
  • human immunodeficiency virus
  • diabetic retinopathy
  • tyrosine kinase
  • optic nerve
  • ionic liquid
  • antiretroviral therapy
  • drug induced
  • combination therapy